JP2003526680A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526680A5
JP2003526680A5 JP2001566703A JP2001566703A JP2003526680A5 JP 2003526680 A5 JP2003526680 A5 JP 2003526680A5 JP 2001566703 A JP2001566703 A JP 2001566703A JP 2001566703 A JP2001566703 A JP 2001566703A JP 2003526680 A5 JP2003526680 A5 JP 2003526680A5
Authority
JP
Japan
Prior art keywords
fentanyl
pharmaceutical formulation
alcohol
polysorbate
congener
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001566703A
Other languages
English (en)
Japanese (ja)
Other versions
JP4969009B2 (ja
JP2003526680A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/006955 external-priority patent/WO2001068140A2/en
Publication of JP2003526680A publication Critical patent/JP2003526680A/ja
Publication of JP2003526680A5 publication Critical patent/JP2003526680A5/ja
Application granted granted Critical
Publication of JP4969009B2 publication Critical patent/JP4969009B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001566703A 2000-03-10 2001-03-02 オピオイド製剤 Expired - Fee Related JP4969009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18826300P 2000-03-10 2000-03-10
US60/188,263 2000-03-10
PCT/US2001/006955 WO2001068140A2 (en) 2000-03-10 2001-03-02 Opioid formulations

Publications (3)

Publication Number Publication Date
JP2003526680A JP2003526680A (ja) 2003-09-09
JP2003526680A5 true JP2003526680A5 (enExample) 2008-04-17
JP4969009B2 JP4969009B2 (ja) 2012-07-04

Family

ID=22692427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001566703A Expired - Fee Related JP4969009B2 (ja) 2000-03-10 2001-03-02 オピオイド製剤

Country Status (4)

Country Link
JP (1) JP4969009B2 (enExample)
AU (2) AU4341401A (enExample)
CA (1) CA2402865A1 (enExample)
WO (1) WO2001068140A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
WO2006047279A2 (en) * 2004-10-21 2006-05-04 University Of Iowa Research Foundation In situ controlled release drug delivery system
US20140179740A1 (en) * 2012-12-21 2014-06-26 Mylan Inc. Stable liquid remifentanil formulations
JP6081240B2 (ja) * 2013-03-13 2017-02-15 テルモ株式会社 レミフェンタニル注射液剤
WO2016038734A1 (ja) 2014-09-12 2016-03-17 テルモ株式会社 レミフェンタニル注射液剤
CN110022865A (zh) * 2016-10-31 2019-07-16 帝国制药美国公司 使用右美托咪定经皮递送装置管理疼痛的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
JPH05331064A (ja) * 1992-05-26 1993-12-14 Sekisui Chem Co Ltd 消炎鎮痛貼付剤
JPH07206903A (ja) * 1994-01-24 1995-08-08 Takeda Chem Ind Ltd 超分子構造型集合体
CA2189351C (en) * 1994-05-13 2008-12-30 Stephen J. Farr Narcotic containing aerosol formulation
JPH09176000A (ja) * 1995-12-28 1997-07-08 Teijin Ltd 医療用貼付剤
WO1997049402A1 (en) * 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. Sustained release sufentanil compositions
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management

Similar Documents

Publication Publication Date Title
JP3756194B2 (ja) 殺寄生虫薬の新規な組み合せ
EP2090165A3 (en) Antifungal composition with enhanced bioavailability
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
SI1526839T1 (sl) Oralne farmacevtske oblike tekočih zdravil z izboljšano biološko uporabnostjo
US20040248901A1 (en) Compositions containing itraconazole and their preparation methods
US20110020440A1 (en) Stable solutions of sparingly soluble actives
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2005065185A3 (en) Temperature-stable formulations, and methods of development thereof
JP2005289996A5 (enExample)
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2000056361A3 (en) Vaccine composition
WO2004108162A3 (en) Controlled release pharmaceutical composition
JPWO1999002158A1 (ja) ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
DK1189620T3 (da) Formulering indeholdende testosteronundecanoat og amerikansk olie
KR20100038188A (ko) 수분산성 건성 약학적 조성물의 신규 제조 방법 및 그에 의해 수득한 약학적 조성물
CA2294033A1 (en) Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
JP2002537242A5 (enExample)
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
JP2003526680A5 (enExample)
US20140371123A1 (en) Aqueous ophthalmic composition
JPH04360833A (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
MXPA04000535A (es) FORMULACIONES ANTIHISTAMINICAS PARA FORMAS DE DOSIFICACION DE CaPSULAS SUAVES.
JP2006524190A5 (enExample)
ES2310550T3 (es) Preparacion liquida acuosa de pranoprofeno.